18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
Fiche du document
2012
- doi: 10.1097/CMR.0b013e32834d3dcb
- issn: 0960-8931
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1097/CMR.0b013e32834d3dcb
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/22027909
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1473-5636
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_5BB3E831A9336
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Tumor spread Spread of cancer Dissemination of cancer Tumor metastasis Tumor dissemination Metastatic cancer Metastases Cancer--Dissemination Neoplasm metastasis Cancer metastasis Cancer--MetastasisCiter ce document
V. Orcurto et al., « 18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study. », Serveur académique Lausannois, ID : 10.1097/CMR.0b013e32834d3dcb
Métriques
Partage / Export
Résumé
PURPOSE: F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and MRI are used for detecting liver metastases from uveal melanoma. The introduction of new treatment options in clinical trials might benefit from early response assessment. Here, we determine the value of FDG-PET/CT with respect to MRI at diagnosis and its potential for monitoring therapy. MATERIAL AND METHODS: Ten patients with biopsy-proven liver metastases of uveal melanoma enrolled in a randomized phase III trial (NCT00110123) underwent both FDG-PET coupled with unenhanced CT and gadolinium-diethylene triamine pentaacetic acid-enhanced liver MRI within 4 weeks. FDG-PET and MRI were evaluated blindly and then compared using the ratio of lesion to normal liver parenchyma PET-derived standardized uptake value (SUV). The influence of lesion size and response to chemotherapy were studied. RESULTS: Overall, 108 liver lesions were seen: 34 (31%) on both modalities (1-18 lesions/patient), four (4%) by PET/CT only, and 70 (65%) by MRI only. SUV correlated with MRI lesion size (r=0.81, P